Company profile: Eureka Therapeutics
1.1 - Company Overview
Company description
- Provider of T-cell therapies via the ARTEMIS Cell Receptor Platform to engineer T cells to target and destroy cancer cells; the E-ALPHA Phage Display Platform to generate specific antibodies against cancer targets, including TCR-mimic antibodies for solid tumors; and an Expanded Access Policy offering investigational cell therapy under certain conditions to patients with serious or life-threatening diseases who have no other treatment options.
Products and services
- E-ALPHA® Phage Display Platform: Architects a human-derived antibody phage library to generate specific antibodies against cancer targets, including TCR‑mimic antibodies for solid tumors
- ARTEMIS® Cell Receptor Platform: Engineers T cells to express proprietary ARTEMIS receptors, leveraging natural T‑cell biology to target and destroy cancer cells through receptor‑mediated recognition
- Expanded Access Policy (EAP): Delivers investigational cell therapy outside clinical trials, under defined conditions, to patients with serious or life‑threatening diseases lacking alternative treatments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eureka Therapeutics
Alentis Therapeutics
HQ: Switzerland
Website
- Description: Provider of CLDN1-targeted therapeutics for CLDN1+ cancers and fibrosis. This clinical-stage Swiss-French biotech develops anti-CLDN1 antibodies and ADCs, including ALE.C04 (mAb for CLDN1+ tumors that opens the collagen barrier), Lixudebart (mAb to reverse liver, kidney, and lung fibrosis), and preclinical ADCs ALE.P02 (delivers a tubulin inhibitor) and ALE.P03 (delivers a topoisomerase I inhibitor) into tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alentis Therapeutics company profile →
Surface Oncology
HQ: United States
Website
- Description: Provider of next-generation cancer immunotherapy treatments based on proprietary insights into novel immunotherapy targets and emerging areas of cancer immuno-biology, advancing multiple preclinical programs with world-leading scientific founders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Surface Oncology company profile →
MedImmune
HQ: United States
Website
- Description: Provider of biologics research and development as the global biologics research and development arm of AstraZeneca, developing medicines for unmet medical needs worldwide and pioneering innovative research and exploring novel pathways across key therapeutic areas including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; and neuroscience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedImmune company profile →
Bright Peak Therapeutics
HQ: Switzerland
Website
- Description: Provider of immunotherapies for cancer and autoimmune diseases, enabling tissue- and cell-specific cytokine targeting with enhanced efficacy. Offerings include Bright Peak Immunoconjugates combining optimized cytokines with antibodies; a chemical protein synthesis platform for novel proteins; and candidates such as BPT567 (PD1-IL18), BPT331 (PD1-IL2), and BPT331CAPS (PD1-IL2CAPS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bright Peak Therapeutics company profile →
Asher Bio
HQ: United States
Website
- Description: Provider of cis-targeted cytokine immunotherapies that selectively activate CD8+ T cells for cancer and chronic viral infections. Pipeline includes AB248, a cis-targeted IL-2 in Phase 1a/1b for solid tumors; AB821, a CD8-targeted IL-21; AB359 for chronic viral infections including HBV; and cis-targeted cytokines to enhance CAR-T and other cell therapies by improving engraftment, persistence, and function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Asher Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eureka Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eureka Therapeutics
2.2 - Growth funds investing in similar companies to Eureka Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eureka Therapeutics
4.2 - Public trading comparable groups for Eureka Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →